LIST OF RARE CANCERS AND ITS RATIONALE

Similar documents
Paolo G. Casali Annalisa Trama

Rare Cancer Perspective in the EUCERD

European Partnership for Action Against Cancer

Table Of Content. EUROCHIP-III "Common Actions"... 2 Summary... 3 Coordinator, Leader contact and partners Outputs... 7

Table Of Content. Information network on rare cancers... 2 Summary... 3 Coordinator, Leader contact and partners Outputs...

How Italy and France take on rare sarcoma cancers

European Cancer Network Aims and Activities

A multi-stakeholder partnership initiative. 10 February 2012

Introduction. Paolo G. Casali

RD-ACTION DISSEMINATION PLAN TABLE I - STAKEHOLDER ANALYSIS

ESMO Clinical Practice Guidelines. ECCO GUIDELINES FORUM Brussels, November 27

European Guide on Quality Improvement in Comprehensive Cancer Control

ANNEX 07 - LATVIA MEDIA GUIDE on CERVICAL CANCER IN LATVIA

Fondazione IRCCS Istituto Nazionale dei Tumori

Soft Tissue Sarcoma: What is best practice?

rare diseases research through National Plans and Strategies

BDA IMPROVING ONCOLOGY DRUG DEVELOPMENT FOR CHILDREN AND ADOLESCENTS NOVEMBER 2013 WORKSHOP ADVANCE PROGRAMME

The value of multidisciplinary tumor boards in cancer care

EUROCHIP-II FINAL SCIENTIFIC REPORT ANNEX 08 REPORT OF ESTONIA

Cancer prevention and control in the context of an integrated approach

Table Of Content. Outputs... 9

3 RD ESO-ESMO-RCE PRECEPTORSHIPS & ClINICAl UPDATE ON RARE ADUlT SOlID CANCERS. 1-3 December 2018 Milan, Italy COURSES AND SEMINARS

RARECARENet country report Belgium

Ruth Howkins Deputy National Coordinator National Cancer Peer Review

Landscape of Cancer Registration in South Africa

The 2003 Council Recommendation on Cancer Screening and the European Initiative on Breast Cancer

How can the patients play their role?

EPAG UPDATE. Lenja Wiehe. European Patient Advocacy Groups Manager, EURORDIS

Integration of Palliative and Oncology Care in patients with lung and other

Fit4RareFit4All Conference Cluj - Napoca 3-4 September 2017

When in doubt, ask an expert

EUROPA DONNA Advocates Guide to the ECIBC European Commission Initiative on Breast Cancer

Center to Advance Palliative Care:

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal

Conducting Successful Oncology Clinical Trials in Asia Pacific: PharmaNet experience using Case Studies

Discovery and validation of novel. Webinar IMI2 - Call 9 Joint influenza vaccine effectiveness studies

ESMO Study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe Preliminary Findings

Workshop on Extrapolation and Evidence Synthesis in the Development and Therapeutic Use of Medicines in Children

ECPC ANNUAL CONGRESS ECPC GENERAL ASSEMBLY

Access to newly licensed medicines. Scottish Medicines Consortium

Pfizer Support to European and International Patient Organisations based in Belgium & Luxembourg in 2016

NCCN Clinical Practice Guidelines Development Process

the man with the method

PHOTO. VHPB/ELPA MEETING Prevention and Control of Viral Hepatitis The role and impact of patients and advocacy groups in and outside Europe

ECIBC overview. Donata LERDA Healthcare Quality Team leader

The EFGCP Children s Medicines Working Party 3 rd Annual Conference EU Paediatric Regulation: First European Experiences & Strategic Outlook

EMPOWERING CIVIL SOCIETY AND PUBLIC HEALTH SYSTEM TO FIGHT TUBERCULOSIS EPIDEMIC AMONG VULNERABLE GROUPS

A06/S(HSS)b Ex-vivo partial nephrectomy service (Adult)

STRATEGIC APPROACH & WORKPLAN 2007

Irish Experts Launch Global Report and Call for Increased Focus on Metastatic Breast Cancer

NORDIC CONFERENCE ON RARE DISEASES

Patronage requested A. ANICHINI (MILAN, ITALY) L. CERCHIETTI (NEW YORK, USA) M.P. COLOMBO (MILAN, ITALY) P. CORRADINI (MILAN, ITALY)

Supplementary Online Content

Rare cancers Medical oncologist Point of View

BREAST CANCER SURGERY

Workshop for OIE national Focal Points for Veterinary Products November 2010, Johannesburg, South Africa. Presentation

ROTTERDAM 12/01/12 ACTIVE SURVEILLANCE FOR LOW RISK PROSTATE CANCER January 2012 Rotterdam, The Netherlands

Prostate Cancer Priority Setting Partnership. PROTOCOL June 2009

Cancer survivorship health and wellbeing clinics. Oncology Patient Information Leaflet

SIOP. 7 TH ESO-SIOP EUROPE MASTERCLASS IN PaEDiatRic OncOlOGy June 2018 nauen Ot Groß Behnitz (Berlin area), Germany.

ESMO 2020 VISION. esmo.org

The European Medicines Agency (EMA)

C o n t e n t s. 2 Introduction. 3 Personal information. 4 Your medical history. 5 PSA results. 7 Healthcare appointments

6 TH ESO-SIOP EUROPE MASTERCLASS IN PAEDIATRIC ONCOLOGY June 2016 Berlin, Germany. Chairs: A. Eggert, DE B. Morland, UK R.

Long-term PHARMacovigilance for Adverse effects in Childhood arthritis focusing on Immune modulatory drugs

CML Adherence Study: Lessons Learned

KDIGO Controversies Conference on Challenges in the Conduct of Clinical Trials in Nephrology

Beyond vaccine introduction: Working together for sustainable, resilient immunization programs Manufacturer perspective

International Collaborations on Sarcomas. Alessandro Gronchi

Turning Mapping into Action

TREAT-NMD Neuromuscular Network

National Cancer Programme. Work Plan 2015/16

Cancer Outcomes and Services Dataset. What is COSD? Skin Cancers Workshop October 2012

CIHRT Exhibit P-2592 Page 1 APPENDIX. ADAPTE Process for the Treatment of In situ Breast Carcinoma. Eastern Health Breast Disease Site Group

Long-term PHARMacovigilance for Adverse effects in Childhood arthritis focusing on Immune modulatory drugs

Hereditary Breast and Ovarian Cancer (HBOC) Information for individuals and families

Vaccine Clinical. Cancer. Group. Working. Trial. Final Workshop, 10 November 2005

Josep M Borras WP7 Health Care University of Barcelona and Spanish Cancer Strategy Brussels, June 23, 2014

Allied Healthcare Professionals Module

The Spanish Society of Medical Oncology: objectives, structure and history

SUMMARY COMPARISON OF NATIONAL PLANS AND PRACTICES. Domenica Taruscio

European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Health in Europe: A Strategic Approach

Cancer Science nd International Conference on Oncology & Cancer Science. August 06-08, 2018 Berlin, Germany. Hosting Organization

Performance Measurement Denmark National Board of Health Niels Hermann

FACTS FOCUS ON. The JARC will focus on the 12 families of rare cancers

Putting Patient Care First

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal

ESMO ACROSS ONCOLOGY. WORLDWIDE. Josep Tabernero. ESMO President. ESMO SUMMIT MIDDLE EAST Friday, 6 th April 2018

Successful collaboration for research development between the NIH and patient organisations

Clinical Evidence in the Daily Work of an Anthroposophic Hospital Dr. med. Harald Matthes, Medical Director, Havelhöhe Hospital in Berlin

OECD WORKSHOP 2000 ON HEALTHY AGEING AND BIOTECHNOLOGY RESEARCH AND POLICY ISSUES

REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS

Table 1 Standards and items to set up a PCU: general requirements and critical mass

TREAT-NMD and the Role of the Industry in Orphan Diseases. Dr. Stefanie Possekel Santhera Pharmaceuticals

PGEU GPUE. Pharmaceutical Group of European Union Groupement Pharmaceutique de l Union Européenne

One Palliative Care Annual Report

Eurocare, the landmark series of

SIOP-E BTG 3 rd European Paediatric Neuro-Oncology Education Day & Training Workshop

Cochrane Rehabilitation Report sullo stato attuale di Cochrane Rehabilitation field e prospettive future nell ottica di ISPRM

COMMISSION OF THE EUROPEAN COMMUNITIES

Transcription:

Forth Eastern European Conference for Rare Diseases and Orphan Drugs Together for Integrative approach to Rare Diseases 13-14 June 2009 Plovdid, Bulgaria LIST OF RARE CANCERS AND ITS RATIONALE Annalisa Trama Fondazione IRCCS "Istituto Nazionale dei Tumori Milan, Italy This project is supported by the Executive Agency for Health and Consumers (EAHC) of the European Commission

Surveillance of rare cancers in Europe Aims To provide a definition of rare cancers and a list of cancers To estimate the burden of rare cancers in Europe To improve the quality of data in cancer registration To develop strategies for the diffusion of information among all the key players Actions To provide figures on incidence, survival, prevalence and mortality for all rare cancers To analyse data quality for a subset of cancers To design a web-site on rare cancers to disseminate results Duration: 3 years (starting date 1 st April 2007)

European coverage 88 European cancer registries (in 22 EU Countries) Population covered 146 millions Selected diagnosis period: 1995-2002 3,180,511 incident cases

Operational definition of rare cancer Rationale Frequency Rare cancers are those cancers that present specific problem in clinical decision making, health care organization and clinical research because of their low frequency Incidence Incidence better indicator for rare cancer Prevalence better indicator for non neoplastic rare diseases Therapy may hopefully impact of the choice of best indicator Awareness of regulatory issues on orphan drugs Threshold for rarity = 6/100.000/year (any threshold is artificial: flexibility in using it)

List of rare cancers Rarity determined by frequency Incidence Not a new classification

The Way to the list Proposal from RARECARE WP4 Pathologists (few), Oncologists and Epidemiologists Consensus workshops Brussels and Treviso WEB based discussion Consensus with scientific bodies

Oncologic societies Association of European Cancer Leagues Invited Breast International Group European Association for Cancer Research European Association of Neuro-Oncology European Association of Nuclear Medicine o Societies under the umbrella ot the European CanCer Organisation (ECCO) European Association of Urology European Breast Cancer Coalition, EUROPA DONNA European Group for Blood and Marrow Transplantation European Oncology Nursing Society European Organisation for Research and Treatment of Cancer o Patient associations European Prostate Cancer Coalition, Europa Uomo European School of Oncology European Society for Medical Oncology European Society for Paediatric Oncology European Society for Therapeutic Radiology and Oncology European Society of Breast Cancer Specialists European Society of Gynaecological Oncology European Society of Oncology Pharmacy European Society of Skin Cancer Prevention European Society of Surgical Oncology Myeloma Euronet

The structure of the list of rare cancers

The Rationale Behind the List First layer Families of tumors (common referral pattern) Organization of health care Second layer Tumors perceived by clinicians as a single disease entity Clinical decision making; clinical research Third layer all WHO tumor entities

The Rationale Behind the List A tumor can be rare under the perspective of clinical decision making but not of health care organization (i.e. bronchiolo-alveolar carcinoma) A tumor can be rare under both perspectives (i.e. sarcoma)

What to do with this list Produce burden indicators Report soon available on the web-site Improve data quality in registration Identify areas in which special efforts are needed

What to do with this list Ideas from the last RARECARE meeting (June 10, 2009) Call for centers of expertise into European reference networks timely, appropriate diagnosis and treatment for rare cancers investigation on the off-label use in rare cancers alternative research methodologies for rare cancer a greater involvement of diseases oriented research communities in providing advice to pharmaceutical industry on the development of new drugs

Thank you for your attention RARECARE web site http://www.rarecare.eu/